<DOC>
	<DOCNO>NCT02100514</DOCNO>
	<brief_summary>This study multicenter , double-blind , randomize study access efficacy , safety tolerability Bococizumab ( PF-04950615 ; RN316 ) subject hyperlipidemia receive background statin therapy .</brief_summary>
	<brief_title>Randomized Clinical Trial Bococizumab ( PF-04950615 ; RN316 ) Subjects With Primary Hyperlipidemia Mixed Dyslipidemia At Risk Of Cardiovascular Events</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Treated statin Fasting LDLC &gt; =100 mg/dL triglyceride &lt; = 400 mg/dL High high risk incur cardiovascular event Pregnant breastfeeding female Cardiovascular cerebrovascular event procedure within 90 day Congestive heart failure NYHA class IV Poorly control hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Primary hyperlipidemia mixed dyslipidemia</keyword>
	<keyword>high risk cardiovascular event</keyword>
	<keyword>multiple cardiovascular disease risk factor .</keyword>
</DOC>